SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)

被引：2
|
作者：
Cohen, S. [1 ]
Alonso-Ruiz, A. [2 ]
Klimiuk, P. A. [3 ,4 ]
Lee, E. [5 ]
Peter, N. [6 ]
Sonderegger, I. [6 ]
Assudani, D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Hosp Cruces, Baracaldo, Spain
[3] Med Univ Bialystok, Bialystok, Poland
[4] Gabinet InternistycznoReumatol, Bialystok, Poland
[5] Inland Rheumatol, Upland, CA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0189
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
    Papp, Kim A.
    Lebwohl, Mark G.
    Thaci, Diamant
    Jaworski, Janusz
    Kwiek, Bartlomiej
    Trefler, Jakub
    Dudek, Anna
    Szepietowski, Jacek C.
    Reznichenko, Nataliya
    Narbutt, Joanna
    Baran, Wojciech
    Kolinek, Joanna
    Daniluk, Stefan
    Bartnicka-Maslowska, Katarzyna
    Reich, Adam
    Andrashko, Yuriy
    Kim, Sunghyun
    Bae, Yunju
    Jeon, Dabee
    Jung, Jinsun
    Lee, Hyunseung
    Pyo, Tina
    Ko, Woori
    BIODRUGS, 2024, 38 (01) : 121 - 131
  • [42] Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
    Kim A. Papp
    Mark G. Lebwohl
    Diamant Thaçi
    Janusz Jaworski
    Bartlomiej Kwiek
    Jakub Trefler
    Anna Dudek
    Jacek C. Szepietowski
    Nataliya Reznichenko
    Joanna Narbutt
    Wojciech Baran
    Joanna Kolinek
    Stefan Daniluk
    Katarzyna Bartnicka-Maslowska
    Adam Reich
    Yuriy Andrashko
    Sunghyun Kim
    Yunju Bae
    Dabee Jeon
    Jinsun Jung
    Hyunseung Lee
    Tina Pyo
    Woori Ko
    BioDrugs, 2024, 38 : 121 - 131
  • [43] SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY
    Edwards, Christopher
    Chyrok, Veronica
    Monnet, Joelle
    Ullmann, Martin
    Vlachos, Pantelis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 707 - 707
  • [44] Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial
    Hanauer, Stephen
    Liedert, Bernd
    Balser, Sigrid
    Brockstedt, Ekkehard
    Moschetti, Viktoria
    Schreiber, Stefan
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 816 - 825
  • [45] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd, Burmester
    Edit, Drescher
    Pawel, Hrycaj
    David, Chien
    Pan Zhiying
    Stanley, Cohen
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3341 - 3352
  • [46] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd Burmester
    Edit Drescher
    Pawel Hrycaj
    David Chien
    Zhiying Pan
    Stanley Cohen
    Clinical Rheumatology, 2020, 39 : 3341 - 3352
  • [47] A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Miranda Limon, Juan Manuel
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Gaylis, Norman B.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Baranauskaite, Asta
    Tseluyko, Vira
    Zhdan, Vyacheslav
    Stasiuk, Barbara
    Milasiene, Roma
    Barrera Rodriguez, Aaron Alejandro
    Cheong, Soo Yeon
    Ghil, Jeehoon
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [49] Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
    Jaworski, Janusz
    Matucci-Cerinic, Marco
    Schulze-Koops, Hendrik
    Buch, Maya H.
    Kucharz, Eugeniusz J.
    Allanore, Yannick
    Kavanaugh, Arthur
    Young, Philip
    Babic, Goran
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [50] Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
    Janusz Jaworski
    Marco Matucci-Cerinic
    Hendrik Schulze-Koops
    Maya H. Buch
    Eugeniusz J. Kucharz
    Yannick Allanore
    Arthur Kavanaugh
    Philip Young
    Goran Babic
    Arthritis Research & Therapy, 21
12345